Bastide le Confort Medical (BLC) AI Stock Analysis

• Market Cap: €172.22M
• Dividend Yield: N/A
• Average Volume (3M): 5.76K
• Price to Earnings (P/E): 330.8
• Beta (1Y): 0.85
• Revenue Growth: -7.28%
• EPS Growth: N/A
• Country: FR
• Employees: 3,635
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): -0.01
• Shares Outstanding: 7,365,078
• 10 Day Avg. Volume: 5,209
• 30 Day Avg. Volume: 5,758
• PEG Ratio: -2.78
• Price to Book (P/B): 3.24
• Price to Sales (P/S): 0.48
• P/FCF Ratio: 5.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: €24.00 ▼(-1.64% Downside)

The overall stock score is primarily impacted by financial performance challenges, including high leverage and declining revenue growth. Technical analysis indicates bearish momentum, and the stock appears overvalued based on its P/E ratio. These factors collectively result in a lower score.

Positive Factors

Operational Efficiency

Strong operational efficiency is evidenced by solid gross and EBITDA margins, which support sustainable profitability and competitive positioning.

Cash Flow Management

Robust cash flow management ensures the company can fund operations and growth initiatives without relying heavily on external financing.

Recurring Revenue Model

A focus on comprehensive home care solutions provides stable financial performance and resilience against market fluctuations.

Negative Factors

High Financial Leverage

Significant leverage increases financial risk and could limit the company's ability to invest in growth or weather economic downturns.

Declining Revenue Growth

A decline in sales performance may indicate weakening market demand or competitive pressures, impacting long-term revenue potential.

Low Net Profit Margin

Low profitability limits the company's ability to reinvest in the business, potentially hindering future growth and shareholder returns.

Bastide le Confort Medical Business Overview & Revenue Model

Company Description

Bastide Le Confort Médical SA engages in the sale and rental of medical equipment in France. The company offers comfort and health products, such as lift chairs, bathroom and well-being products, pillows and cushions, seats, phones keys, measuring devices, technical aids, fitness products, blood pressure monitors, and pillboxes ; and incontinence products, including absorbent and support briefs, anatomical protections, protections for men and women, disposable mattress pads, PVC panties, and hygiene and body care products. It also provides medical materials comprising home support products wheel chairs, electric scooters, walkers, bed tables and rails, and transfer aids, air mattress, sick lifts, and standers; and medical equipment consisting of consumables, care and dressings, hygiene and disinfection products, outfits and briefcases, and other medical equipment, as well as home support services for elderly, senior, or disabled. It offers its products through approximately 130 stores, as well as through an online store. The company was founded in 1977 and is headquartered in Caissargues, France.

How the Company Makes Money

Bastide le Confort Medical generates revenue through multiple key streams, including the sale of medical equipment and supplies, as well as home healthcare services. The company earns significant income from direct sales to consumers and healthcare institutions, alongside rental agreements for medical devices. Additionally, BLC has established partnerships with healthcare professionals and institutions that facilitate referrals and enhance service offerings. Their focus on providing comprehensive home care solutions allows for recurring revenue through ongoing service contracts and maintenance agreements, contributing to stable financial performance.

Bastide le Confort Medical Financial Statement Overview

Summary

Bastide le Confort Medical exhibits strengths in operational efficiency and cash flow management, with solid gross and EBITDA margins and strong free cash flow growth. However, challenges include declining revenue growth, low net profit margins, and high financial leverage.

Income Statement

Bastide le Confort Medical shows a strong gross profit margin of approximately 68%, indicating efficient cost management. However, the net profit margin is extremely low at 0.1%, reflecting challenges in converting revenue into profit. The revenue growth rate is negative at -9.1%, suggesting a decline in sales performance. Despite these challenges, the company maintains a stable EBIT margin of 8.4% and an EBITDA margin of 20.8%, highlighting operational efficiency.

Balance Sheet

The company has a high debt-to-equity ratio of 5.7, indicating significant leverage and potential financial risk. Return on equity is very low at 0.7%, suggesting limited profitability for shareholders. The equity ratio is also low, reflecting a reliance on debt financing. These factors suggest a need for improved financial stability and risk management.

Cash Flow

Bastide le Confort Medical demonstrates strong cash flow performance with a significant free cash flow growth rate of 178.6%. The operating cash flow to net income ratio is 0.51, indicating good cash generation relative to net income. The free cash flow to net income ratio is 0.41, showing a healthy conversion of earnings into cash. These metrics reflect robust cash flow management despite the company's profitability challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	491.18M	491.18M	529.75M	508.03M	468.30M	444.07M
Gross Profit	48.14M	333.00M	354.44M	333.73M	306.80M	280.26M
EBITDA	101.42M	102.03M	107.20M	98.15M	89.83M	88.30M
Net Income	528.00K	528.00K	-900.00K	12.05M	13.68M	13.45M
Balance Sheet
Total Assets	661.03M	661.03M	647.07M	657.08M	632.55M	569.11M
Cash, Cash Equivalents and Short-Term Investments	25.49M	25.49M	23.62M	36.71M	22.13M	33.74M
Total Debt	411.16M	411.16M	408.65M	427.39M	419.23M	357.62M
Total Liabilities	589.73M	589.73M	566.34M	568.99M	545.89M	484.05M
Stockholders Equity	72.13M	72.13M	79.77M	87.65M	84.56M	81.31M
Cash Flow
Free Cash Flow	11.79M	41.74M	10.64M	36.65M	-6.51M	19.62M
Operating Cash Flow	71.87M	101.82M	66.04M	90.28M	46.76M	66.13M
Investing Cash Flow	-56.44M	-56.44M	-43.65M	-76.27M	-104.74M	-73.45M
Financing Cash Flow	-4.33M	-4.33M	-35.55M	-7.89M	29.43M	1.34M

Bastide le Confort Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BLC, the sentiment is Negative. The current price of 24.4 is below the 20-day moving average (MA) of 25.02, below the 50-day MA of 24.92, and below the 200-day MA of 26.93, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 35.72 is Neutral, neither overbought nor oversold. The STOCH value of 10.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BLC.

Bastide le Confort Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LNA	61 Neutral	€252.17M	11.94	6.64%	2.73%	13.31%	-13.07%
ALERS	55 Neutral	€243.13M	103.58	1.32%	―	12.47%	-65.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLC	49 Neutral	€172.22M	330.76	3.97%	―	-7.28%	―

Bastide le Confort Medical Corporate Events

Bastide Group Releases Semi-Annual Financial Report

The Bastide Group has released its semi-annual financial report for December 31, 2024, making it available to the public and filing it with the Autorité des Marchés Financiers. This report can be accessed on their website, and the next financial update will be the publication of the 3rd quarter 2024-2025 revenue on May 15, 2025. This release underscores Bastide’s commitment to transparency and may impact investor relations and market positioning.